Merck and Schering-Plough to Complete Merger Today|
New Merck Will Begin Combined Operations Tomorrow
Global Health Care Leader Poised for Sustainable Growth Through
Innovations for Patients
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Nov. 3, 2009--
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:
SGP) today announced that they will complete their merger shortly
after 4:00PM ET today. The companies will begin combined operations
tomorrow, No... |
| November 03, 2009 | Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C| Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in ... |
| November 02, 2009 | Schering-Plough Announces Sponsorship of Rabies-Control Projects in India| Program Focus: Community Education and Mass Vaccination of Dogs in 10 Villages
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support... |
| November 02, 2009 | Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies| KENILWORTH, N.J., Nov 02, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass po... |
| November 02, 2009 | Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting|
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus (HCV) genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.
Boceprevir is an investigational HCV protease inhibitor. Phase III registration studie... |
| November 01, 2009 | U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma|
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
Schering-Plough will work closely with FDA to respond to outstanding concerns related to the ... |
| October 30, 2009 | Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for Merger| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK - News) and Schering-Plough Corporation (NYSE: SGP - News) today announced that they have received clearance from the U.S.
Federal Trade Commission (FTC), the Swiss Competition Commission and the
Canadian Competition Bureau for their proposed merger.
The companies said that the FTC terminated the waiting period under the
Hart-Scott-... |
| October 29, 2009 | Merck and Schering-Plough Receive Approval From European Commission for Merger | WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Oct. 23, 2009--
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:
SGP) today announced that they have received clearance from the European
Commission (EC) under the EC Merger Regulation for their proposed merger.
“Approval from the European Commission marks a key milestone for the
completion of our transaction with Schering-Plough,” said Richard T.
Clark, chairma... |
| October 23, 2009 | Schering-Plough Reports Financial Results for 2009 Third Quarter| KENILWORTH, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.
"This quarter we delivered operational top-line growth, reconciled bottom-line growth and major pipeline successes. We powered through - even in the face of tough global economic and currency headwinds," said Fred Hassan, chairman and CEO. "As we near the anticipated close of our combination with Merck, we are proud of how our colle... |
| October 22, 2009 | Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and PEGINTRON(R) Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting| KENILWORTH, N.J., Oct 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough (NYSE: SGP) today announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3. Researchers will present sustained virologic response (SVR) data on boceprevir triple combination therapy in treatment-naive HCV genotype 1 patients... |
| October 15, 2009 | Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Concept Study|
BOXMEER, Netherlands, Oct. 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
"We are encouraged by the continuation of the clinical development program of SCH 900795 after interim results of Nobilon's first ever Phase I study had demonstrated that the pri... |
| October 13, 2009 | Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings|
KENILWORTH, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) is scheduled to announce its sales and earnings results for the 2009 third quarter on Thursday, Oct. 22, 2009.
At approximately 7:15 a.m. (EDT) on that day, Schering-Plough will conduct a conference call to review results for the 2009 third quarter. Fred Hassan, Schering-Plough's chairman and CEO, and other members of management will host the conference call.
To listen live to the ca... |
| October 12, 2009 | Intervet/Schering-Plough Animal Health Announces Sponsorship Supporting Milk Producers In Malawi|
BOXMEER, Netherlands, Oct. 8 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health today announced that it has initiated a multi-year sponsorship project, supporting the Shire Highlands Milk Producers Association (SHMPA) in Malawi, a developing country in southeast Africa. The primary objective of the project is to support smallholder dairy farmers in the Shire Highlands to improve their capabilities to manage the milk production process.
Intervet/Schering-Plough Animal Healt... |
| October 08, 2009 | SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector| HORSHAM, Pa. and KENILWORTH, N.J., Oct. 6 /PRNewswire/ -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS).
In the European Union, SIMPONI is approved as a 50 mg subcutaneous inje... |
| October 06, 2009 | FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma|
GAITHERSBURG, Md., Oct. 5, /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.
PEGINTRON is a longer-acting form of the protein interferon alfa-2b (INTRON® A). PEGINTRON is administered subcutaneously once-we... |
| October 05, 2009 | Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock|
KENILWORTH, N.J., Sept. 18 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Nov. 30, 2009, to shareholders of record at the close of business on Oct. 26, 2009. As of June 30, 2009, there were 1,633,938,697 common shares outstanding.
The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferre... |
| September 18, 2009 | Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients| VICTOR-E1 Study Results Sustained through 96 Weeks; Data Presented at ICAAC Annual MeetingSAN FRANCISCO, Sept 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The results showed that vicriviroc plus optimized background therapy achieved durable virolo... |
| September 14, 2009 | Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study| Findings from 52-week study presented at major European psychiatry congress demonstrate time to relapse significantly longer with SAPHRIS
ISTANBUL, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the primary efficacy endpoint, was significantly longer with SAPHRIS than w... |
| September 14, 2009 | Three Directors Set For Newly-Combined Merck| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--As part of the pending merger agreement between Merck & Co., Inc. (NYSE: MRK - News) and Schering-Plough Corporation (NYSE: SGP - News), the companies today announced that the following three representatives from the current Schering-Plough board of directors are expected to remain on the Board of the newly combined company upon completion of the merger: C. Robert Kidder, Patricia F. Russo, and Craig B. Thompson, M.D.
... |
| September 03, 2009 | Dieter Lutticken Award 2008 for Alternatives in Animal Testing Presented to Dr. Ivo Claassen (The Netherlands)|
ROME, Sept 03, 2009 /PRNewswire via COMTEX/ -- The Dieter Lütticken Award 2008 for alternatives in animal testing was presented today to Dr. Ivo Claassen for developing an alternative quality control method for poultry vaccines at the Central Veterinary Institute (CVI) in Lelystad (the Netherlands). The euro 20,000 award was presented during a special session celebrating the 50th anniversary of the launch of the 3R principles by Russell and Burch during the 7th World Congres... |
| September 03, 2009 | New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day| The leading over-the-counter allergy brand is available in both 12- and 24-hour formulations so sufferers can choose the duration that best meets their needs
KENILWORTH, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the introduction of CLARITIN 12-Hour, the only 12-hour allergy medicine found in the allergy aisle. New CLARITIN 12-Hour lasts all day and provides effective, non-drowsy relief from the worst indoor and outdoor allergy symptoms. ... |
| September 01, 2009 | Merck CEO Announces Structure and Global Leadership Team for New Merck|
New Structure to Capitalize on Growth Opportunities in Emerging
Markets, Biologics, Vaccines, Animal Health and Consumer Health Care
Merger Planning on Track; Expected to Close in Fourth Quarter
New Merck Organized to Maximize Broader Product Portfolio With a
Robust R&D Pipeline to Better Meet Patient Needs
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Aug. 31, 2009--
Richard T. Clark, chairman, president and chief executiv... |
| August 31, 2009 | Schering-Plough Announces Two European Filings| Validations received for combination inhaled asthma maintenance treatment and for novel oral contraceptive
KENILWORTH, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age... |
| August 26, 2009 | Video:Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults| --First psychotropic drug to receive initial approval for both indications simultaneouslyKENILWORTH, N.J., Aug 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS((R)) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRI... |
| August 14, 2009 | Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)| KENILWORTH, N.J., Aug. 11 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals &
Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the
generic manufacturing of certain formulations of CLARINEX (desloratadine).
The agreement marks the end of all pending litigations filed and
consolidated since 2006 in the U.S. District Court for the District of New
Jersey against several generic drug manufacturing co... |
| August 11, 2009 | Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours| Schering-Plough introduces an over-the-counter antihistamine eye drop that works in minutes to relieve the itch of allergy eyes
KENILWORTH, N.J., Aug. 11 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced the launch of CLARITIN Eye, an
antihistamine eye drop strong enough to control itchy eyes all day or all
night. Found in the eye care aisle wherever over-the-counter products are
sold, CLARITIN Eye works in minutes to relieve the itch of allergy e... |
| August 11, 2009 | Schering-Plough Shareholders Approve Merger With Merck| BOSTON, Aug. 7 /PRNewswire-FirstCall/ -- Schering-Plough Corporation
(NYSE: SGP) announced the voting results of a special shareholders meeting
today regarding the proposed merger with Merck & Co., Inc. More than 99
percent of votes cast voted to approve the merger agreement, with more than 78
percent of common shares voting.
"Today's vote by our shareholders reflects the potential they see to
create a strong global health care leader by combining these two companies,"
said Fred ... |
| August 07, 2009 | Schering-Plough to Webcast Special Meeting of Shareholders| KENILWORTH, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) will provide a live Webcast of its Special
Shareholders Meeting being held on Friday, August 7, 2009, at 1:30 p.m. (EDT)
regarding the proposed merger between Schering-Plough and Merck & Co., Inc.
Originating from Boston, the Webcast will be available to all interested
parties via the corporate Web site, www.schering-plough.com.
Those wishing to listen live to the Webcast of the Special Meeti... |
| August 06, 2009 | Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe)| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J., Aug 05, 2009 (BUSINESS WIRE) -- Merck & Co., Inc., Schering-Plough Corporation and the companies'
cholesterol joint venture, Merck/Schering-Plough Pharmaceuticals (MSP),
today announced that they have entered into agreements to resolve, for a
total fixed amount of $41.5 million, civil class action litigation
currently pending against the companies relating to the purchase or use
of VYTORIN and ZETIA. The MSP joi... |
| August 05, 2009 | FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia| KENILWORTH, N.J., July 30 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that the U.S. Food and Drug
Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted
unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective
and safe for the acute treatment of manic or mixed episodes associated with
bipolar I disorder in adults and in favor of use in acute treatment of
schizophrenia in adults. If approved by FDA, SAPHRIS wo... |
| July 30, 2009 | Sanofi-aventis to Acquire Merck's Interest in Merial | Agreement includes option for sanofi-aventis to combine Merial with Intervet/Schering-Plough Animal Health in new equally owned joint venture with the new Merck
PARIS & WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jul. 30, 2009--
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Merck & Co., Inc.
(NYSE: MRK) today announced that the companies have signed a definitive
agreement under which Merck will sell its 50 percent interest in the
companies' c... |
| July 30, 2009 | SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia| KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that its investigational agent
SAPHRIS(R) (asenapine) met the primary endpoint over one year of treatment in
an extension study in patients with predominant, persistent negative symptoms
of schizophrenia.
Negative symptoms of schizophrenia include apathy, lack of emotion and
poor social functioning, among others. In the study, these symptoms were
assessed using the validate... |
| July 24, 2009 | Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck| KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported a proposed settlement, subject to Court
approval, to resolve litigation seeking to enjoin the planned merger with
Merck & Co., Inc., and other forms of relief. The consolidated class action
lawsuits, previously reported in the merger proxy statement/prospectus filed
June 25, 2009, were filed in U.S. District Court for the District of New
Jersey.
The proposed settlement, as m... |
| July 24, 2009 | Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma| KENILWORTH, N.J., July 22, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate has been filed in the United States and accepted for review by the U.S. Food and Drug Administration (FDA). Schering-Plough is seeking marketing approval from the FDA of the mometasone furoate/formoterol fumarate combination for the maintenance treatment of asthma in patients 12 years of a... |
| July 22, 2009 | Schering-Plough Reports Financial Results for 2009 Second Quarter| Click here to view a PDF version of this release
--Diversification Strategy and Strong Execution Continue to Drive Solid Performance;
--Robust Pipeline Continues To Advance and Build Long-Term Value
KENILWORTH, N.J., July 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 second quarter.
"Our successful diversification strategy and strong execution by our people have given us the strength to again power ... |
| July 21, 2009 | Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe)| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J., Jul 15, 2009 (BUSINESS WIRE) -- Merck & Co., Inc. and Schering-Plough Corporation and the companies'
cholesterol joint venture, Merck/Schering-Plough Pharmaceuticals, today
said they have reached a civil settlement with a multistate group of
attorneys general representing 35 states and the District of Columbia
who investigated whether the companies violated state consumer
protection laws in connection with the E... |
| July 15, 2009 | Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV| CCR5 Antagonist Evaluated in Novel Nucleoside-Sparing Regimen Designed to
Provide Additional Treatment Options, Preserve other HIV Drugs for Subsequent Use
KENILWORTH, N.J., July 15 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that it has extended to stage two an
ongoing Phase II clinical study with vicriviroc, its investigational CCR5
antagonist, for use in first-line therapy of adult treatment-naive
HIV-infected patients with R5-type virus... |
| July 15, 2009 | REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients| KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the
company's country operation in Japan, has received marketing approval for
REMERON(R) /Reflex(R) (mirtazapine)15 mg Tablets for the treatment of major
depressive disorder.(1) The product was developed jointly with Meiji Seika
Kabushiki Kaisha, Ltd. Schering-Plough and Meiji Seika will market the product
under the trade names, REMERON(R) and Reflex(R),... |
| July 09, 2009 | ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients| KENILWORTH, N.J., July 9, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER (mometasone furoate dry powder inhaler) for the treatment of bronchial asthma in adults.(1)
"We are pleased to announce the approval of the ASMANEX TWISTHALER in Japan," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-... |
| July 09, 2009 | Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa| --Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study
AMSTERDAM, July 1, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corp., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant fol... |
| July 01, 2009 | Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings| KENILWORTH, N.J., June 29 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) is scheduled to announce its sales and earnings
results for the 2009 second quarter on Tuesday, July 21, 2009.
At approximately 7:45 a.m. (EDT) on that day, Schering-Plough will conduct
a conference call to review results for the 2009 second quarter. Fred Hassan,
Schering-Plough's chairman and CEO, and other members of management will host
the conference call.
To listen live to the cal... |
| June 29, 2009 | SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis| --Positive Opinion Recommends Approval of New Anti-TNF Therapy in Three Rheumatic Diseases with Novel SmartJect(TM) Autoinjector
HORSHAM, Pa. and KENILWORTH, N.J., June 26, 2009 /PRNewswire-FirstCall via COMTEX/ -- Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending the approval of SIMPONI(TM) (golimumab) as a once-m... |
| June 26, 2009 | New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus| --Vaccine Against Canine Flu Granted Conditional License by USDA
ROSELAND, N.J., June 23, 2009 /PRNewswire via COMTEX/ -- Intervet/Schering-Plough Animal Health, the global leader in veterinary biologicals, today announced the availability of the first vaccine against canine influenza virus (CIV), which was granted a conditional product license by the U.S. Department of Agriculture (USDA) on May 27, 2009, for use by veterinarians in the United States. (http://www.aphis.usda.gov/newsroom/conte... |
| June 23, 2009 | Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock| KENILWORTH, N.J., June 23, 2009 /PRNewswire-FirstCall via COMTEX/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 31, 2009, to shareholders of record at the close of business on August 7, 2009. As of March 31, 2009, there were 1,628,335,093 common shares outstanding.
The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convert... |
| June 23, 2009 | Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger| WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jun. 22, 2009--
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:
SGP) today announced that they each have received a request for
additional information from the U.S. Federal Trade Commission (FTC) with
respect to their previously announced proposed merger. The request for
information from the FTC, often referred to as a “second request,” was
anticipated as part of the r... |
| June 22, 2009 | The New York Yankees' Mark Teixeira, National Foundation For Cancer Research, and the Makers of COPPERTONE SPORT(R) Launch 'Help Strike Out Sun Damage' Program| Program Asks Athletes and Fans Alike to Educate and Protect Themselves
against Incidental Sun Damage
KENILWORTH, N.J., June 17 /PRNewswire-FirstCall/ -- With the first day of
summer around the corner, Schering-Plough Corporation (NYSE: SGP), the makers
of COPPERTONE(R), announced today that they have teamed up with New York
Yankees' first baseman Mark Teixeira and the National Foundation for Cancer
Research (NFCR) for "Help Strike Out Sun Damage," a campaign to raise
awareness abo... |
| June 17, 2009 | New Analysis Shows Efficacy of Simponi™ (GOLIMUMAB) in Anti-TNF Experienced Rheumatoid Arthritis Patients| Anti-TNF Experienced Patients Demonstrated Improvements with Every Four-Week Subcutaneous
SIMPONI Despite Previous Medication or Reason for Discontinuation
COPENHAGEN, Denmark - 10 June 2009 - A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI™ (golimumab) once every four weeks experie... |
| June 10, 2009 | Two-Year Data Show Patients Receiving Simponi™ (GOLIMUMAB) Experienced Sustained Improvements in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondyitis| Long-Term Data in Patients Receiving Every Four-Week Subcutaneous SIMPONI
Presented at 2009 EULAR Annual Congress
COPENHAGEN, Denmark - 10 June 2009 – Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) injections of SIMPONI™ (golimumab) 50 mg or 100 mg every four weeks provided persistent improvements in the signs and symptoms in patients with psoriatic arthritis (PsA) and ankylosing spondylitis... |
| June 10, 2009 | New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives| --Three-of-Four Patients Surveyed Experience Daily Pain From Rheumatoid Arthritis Despite Current Treatment; Findings Unveiled at the European League Against Rheumatism Annual Congress of Rheumatology
COPENHAGEN, Denmark, June 10, 2009 /PRNewswire-FirstCall via COMTEX/ -- Results from the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey of more than 500 rheumatoid arthritis (RA) patients throughout Europe and Canada revealed a majority of patients still suffer from pain ... |
| June 10, 2009 | Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder| KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that the European Medicines Agency
(EMEA) has validated (accepted for review) the company's Marketing
Authorization Application (MAA) for SYCREST(R) (asenapine) sublingual tablets
for the treatment of schizophrenia and manic episodes associated with bipolar
I disorder. The application will follow the Centralized Procedure.
The MAA for SYCREST includes data from the asenapine ... |
| June 02, 2009 | Schering-Plough and Merck Provide Update on Distribution Agreement| Please Click Here for PDF Version of release.
KENILWORTH, NJ and WHITEHOUSE STATION, N.J., May 27, 2009 - Schering-Plough has been notified that Johnson & Johnson, as a result of the proposed merger between Schering-Plough and Merck, has initiated arbitration proceedings to resolve the parties' dispute over whether Johnson & Johnson can terminate the distribution agreement relating to Schering-Plough's rights to REMICADE and SIMPONI.
While the initiation of the proceeding... |
| May 27, 2009 | Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males| Specially designed microsite (www.meettheburns.com) targets first time
athlete's foot sufferers and parents.
KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced the arrival of TINACTIN(R) CHILL, an
antifungal spray for the treatment of athlete's foot. TINACTIN CHILL is
available in two formulations, liquid spray and deodorant powder spray.
(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 )
To view the ... |
| May 19, 2009 | Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD| --Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD
KENILWORTH, N.J., May 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The changes will result in Schering-P... |
| May 19, 2009 | Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair| COPPERTONE Continues Legacy of Innovation with New Research on
Antioxidant-Enhanced Suncare
KENILWORTH, N.J., May 14 /PRNewswire-FirstCall/ -- In time for warmer
weather, Schering-Plough (NYSE: SGP), introduces COPPERTONE(R), NutraShield(R)
with Dual Defense(R), a new line of sunscreens enriched with antioxidants to
help promote natural skin repair by neutralizing harmful free radicals created
by UV exposure.
Topical antioxidants can offer cosmetic skin-enhancing benefits wh... |
| May 14, 2009 | Schering-Plough Schedules Webcast For Annual Meeting of Shareholders| KENILWORTH, N.J., May 11 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) will hold its Annual Meeting of Shareholders on
Monday, May 18, 2009, in Chicago at 7:30 a.m. (CDT) (8:30 a.m. EDT). On that
day, a live Webcast of the meeting will be available to all interested parties
via the corporate Web site, www.schering-plough.com.
At the Annual Meeting, Fred Hassan, chairman and CEO, will report to
shareholders on the company's performance and progress.
The pro... |
| May 11, 2009 | Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery| RED-CABG Trial Initiates Patient Recruitment for Potentially Life-Saving
Agent
KENILWORTH, N.J., May 11 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced the start of patient enrollment in
RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially
first-in-class adenosine regulating agent (ARA). Acadesine was licensed from
PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical
company. Acadesine is being studied a... |
| May 11, 2009 | Schering-Plough Flips the Switch on 1.7 MW Rooftop Solar Panel System, One of the Largest in N.J., North America| Local 5th Graders Learn About the Science Behind Energy Production
SUMMIT, N.J., April 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) welcomed local and state officials, and a class of fifth graders, to celebrate the completion of a 1.7 megawatt solar energy system. With panels located atop seven buildings at the company's Summit, N.J., site, the system is one of the largest photovoltaic rooftop installations in New Jersey and North America. Chairman and... |
| April 29, 2009 | Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting| Final results from three large PEGINTRON(TM) clinical studies address key
questions in the treatment of hepatitis C
COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported that final results of three large
PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding
questions in the hepatitis C research community and provide important
insights. The results of the studies, involving a total of more than 2,700
pa... |
| April 27, 2009 | Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients| 48-week investigational regimen yielded nearly double SVR rate compared to
standard of care
Update on next-generation HCV protease inhibitor SCH 900518 presented at
EASL annual meeting
COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported that final results of the HCV SPRINT-1
study showed boceprevir, its investigational oral hepatitis C protease
inhibitor, in combination with peginterferon alfa-2b and ribavirin,
signif... |
| April 23, 2009 | Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality| "Don't Blow It" Online Health Game Launches; Low-Allergenic Tree Planted
for Each New Player, Up to 20,000 Trees
KENILWORTH, N.J., April 22 /PRNewswire/ -- Does it seem that allergy
season starts earlier and there's more pollen every year? Many scientists now
believe that global climate change could be partly to blame.(1) To educate
people about nasal allergies and the environment, the makers of NASONEX
(mometasone furoate monohydrate) Nasal Spray, 50 mcg* have teamed up with
Amer... |
| April 22, 2009 | Schering-Plough Reports Financial Results for 2009 First Quarter| Click here to view a PDF version of this release
Transformed Company Delivers Solid Financial Performance,
Continues to
Advance Industry-Leading Late-Stage Pipeline
KENILWORTH, N.J., April 21 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported financial results for the 2009 first
quarter.
"Schering-Plough powered through to deliver a solid performance in the
first quarter," said Fred Hassan, chairman and CEO. "We overcame difficult
currency ... |
| April 21, 2009 | Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis| Apr 13, 2009 /PRNewswire via COMTEX/ -- Canadian Approval Is World's First Regulatory Approval for SIMPONI
HORSHAM, Pa. and KENILWORTH, N.J., April 13 /PRNewswire-FirstCall/
Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) today
announced that Health Canada has granted approval of SIMPONI (TM) (golimumab)
as a once-monthly, subcutaneous therapy for the treatment of moderately to
severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA)
and active an... |
| April 13, 2009 | Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay| BOXMEER, Netherlands, April 7 /PRNewswire-FirstCall/ --
Intervet/Schering-Plough Animal Health today announces that the Dieter
Luetticken Award 2008 for alternatives in animal testing goes to Dr. Ivo
Claassen for a project that he has managed at the Central Veterinary Institute
(CVI), Lelystad (the Netherlands). The announcement was made by Prof. Coenraad
Hendriksen, chairperson of an independent expert jury panel and Professor of
Alternatives to Animal Testing at Utrecht University (t... |
| April 07, 2009 | Schering-Plough Announces Results of the Early ACS Trial| Early Use of INTEGRILIN(R) Investigational Dosing is Not Superior to
Delayed Provisional Use in Patients with High-Risk Acute Coronary Syndrome,
Study Finds
KENILWORTH, N.J., March 30 /PRNewswire-FirstCall/ -- In a study presented
today at the 58th annual Scientific Sessions of the American College of
Cardiology and simultaneously published by The New England Journal of
Medicine, researchers reported that a strategy using an upstream,
investigational dose of INTEGRILIN(R) (eptifib... |
| March 30, 2009 | EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year| --
KENILWORTH, N.J., March 30, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cleveland, Tenn., Plant Recognized for Efficient Energy Performance
The U.S. Environmental Protection Agency (EPA) has named Schering-Plough Corporation as a 2009 ENERGY STAR Partner of the Year for outstanding energy management and reductions in greenhouse gas emissions. The company's accomplishments will be recognized at an awards ceremony in Washington, D.C., on March 31, 2009.
In addition, Schering-Plough's plant i... |
| March 30, 2009 | Video: New Children's Storybook Helps Parents Teach Their Children With Asthma About Their Condition| Schering-Plough partners with the Allergy & Asthma Network Mothers of
Asthmatics to tell the delightful story of "Breathless Bethany Buttercup"
KENILWORTH, N.J., March 24 /PRNewswire/ -- Asthma is the most common
chronic condition among children, with approximately 6.8 million children
currently with asthma in the United States.(1,2) It accounts for almost 13
million missed school days each year and is the third-ranking cause of
hospitalization among those younger than 15 years of ... |
| March 24, 2009 | Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM)| - Safe Driving Pledge Unveiled as Part of Nationwide Awareness Campaign -
KENILWORTH, N.J., March 18 /PRNewswire-FirstCall/ -- This spring allergy
season, Schering-Plough (NYSE: SGP), maker of the non-drowsy allergy medicine,
CLARITIN, is continuing its partnership with allergy sufferer and NASCAR
driver Carl Edwards to encourage safe driving practices.
To view the Multimedia News Release, go to:
http://www.prnewswire.com/mnr/claritin/37512/
"Drowsy driving is da... |
| March 18, 2009 | Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development| BOXMEER, Netherlands, March 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
The candidate vaccine is composed of the three attenuated Influenza viruses recommended by the World Health Org... |
| March 13, 2009 | Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study| A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet
Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well
Tolerated When Given With Standard Platelet Therapy
KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a
Schering-Plough Corporation (NYSE: SGP) Phase II trial of SCH 530348, a novel
oral thrombin receptor antagonist (TRA), were published today in The Lancet
and demonstrated that the investigational antiplatelet compound met its
... |
| March 12, 2009 | Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings| KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) is scheduled to announce its sales and earnings
results for the 2009 first quarter on Tuesday, April 21, 2009.
At 7:30 a.m. (EDT) on that day, Schering-Plough will conduct a conference
call to review results for the 2009 first quarter. Fred Hassan,
Schering-Plough's chairman and CEO, and other members of management will host
the conference call.
To listen live to the call, dial 1-877-... |
| March 12, 2009 | FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C| New use for PEGINTRON(TM) and REBETOL(R) offers certain patients a second
chance to achieve treatment success
KENILWORTH, N.J., March 11 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that the U.S. Food and Drug
Administration (FDA) has approved new labeling for PEGINTRON(TM)
(peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy
for treating chronic hepatitis C in patients 3 years of age and older with
compensated liver dise... |
| March 11, 2009 | Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference| KENILWORTH, N.J., March 9 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) will not present at the Barclays Capital Global
Healthcare Conference in Miami, on Tuesday, March 10, as previously planned.
We will be participating in various investor and employee communications
related to the merger agreement with Merck announced earlier today, and
therefore, will not be able to attend the conference.
Schering-Plough is an innovation-driven, science-centered global healt... |
| March 09, 2009 | Merck and Schering-Plough to Merge| Combined Company Positioned for Sustainable Growth Through Scientific Innovation and a Stronger, More Diversified Product Portfolio
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Mar. 9, 2009--
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE:
SGP) today announced that their Boards of Directors have unanimously
approved a definitive merger agreement under which Merck and
Schering-Plough will combine, under the name Merck, in a st... |
| March 09, 2009 | Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference| KENILWORTH, N.J., March 5 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) will provide a live audio webcast of a presentation by
David Nicholson, Ph.D., senior vice president, Global Project Management &
Drug Safety, Schering-Plough Research Institute, at the Barclays Capital
Global Healthcare Conference in Miami on Tuesday, March 10, at approximately 2
p.m. EDT. Nicholson is expected to talk about the company's R&D pipeline and
select projects in development.
A... |
| March 05, 2009 | European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors| Schering-Plough Receives EU and US Approvals for Intravenous Formulation
of Temozolomide As Well As EU Approval for Oral Temozolomide Sachet
Presentation
KENILWORTH, N.J., March 5 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that the European Commission and the
US FDA both approved the intravenous (IV) formulation of temozolomide as an
alternative to the already approved oral form of the drug. Temozolomide is
marketed as TEMODAL(R) in the EU a... |
| March 05, 2009 | Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France| 100 Percent Purified Seawater Helps Users Breathe Freely
KENILWORTH, N.J., March 3 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced the launch of AFRIN(R) PureSea(TM)
Hydrating Nasal Rinse, the only nasal rinse product entirely made of 100
percent purified sea water. Available in the cold/allergy aisle at retailers
nationwide, AFRIN PureSea is clinically proven to cleanse nasal and sinus
passages of mucus, pollutants, and irritants so users can brea... |
| March 03, 2009 | Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock| KENILWORTH, N.J., Feb. 27 /PRNewswire-FirstCall/ -- The Board of Directors
of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend
of 6.5 cents per common share. Payment will be made on May 26, 2009, to
shareholders of record at the close of business on May 1, 2009. As of Jan.
31, 2009, there were 1,626,412,285 common shares outstanding.
The Board of Directors today also declared a quarterly dividend of $3.75
per share on the 2007 Mandatory Convertible Pref... |
| February 27, 2009 | Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries| KENILWORTH, N.J. and BOXMEER, Netherlands, Feb. 23 /PRNewswire-FirstCall/
-- Schering-Plough Corporation (NYSE: SGP) today announced a license agreement
between Nobilon, Schering-Plough's human vaccine business unit, and the World
Health Organization (WHO) to provide access to pandemic influenza vaccine
manufacturing technology to developing countries.
Fred Hassan, chairman and CEO, said, "This project demonstrates
Schering-Plough's strong commitment to innovation and to providing ... |
| February 23, 2009 | Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder| --Response submitted within one month of FDA complete response letterKENILWORTH, N.J., Feb 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has responded to the U.S. Food and Drug Administration (FDA) complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets, which was received in January 2009. SAPHRIS is under review for the acute treatment of schizophrenia in adults and for the acute treatment of manic or mixed episode... |
| February 20, 2009 | Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards| - Partnership Drives Home Importance of Being Alert and Focused on and off
the Racetrack -
KENILWORTH, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE:
SGP), maker of the top-selling allergy medicine, CLARITIN, announces its
second Sprint Cup racing season as a sponsor of NASCAR star and long-time
allergy sufferer Carl Edwards. Edwards, who takes non-drowsy CLARITIN to treat
his allergy symptoms, will drive the No. 99 CLARITIN Ford Fusion during the
April NASCAR Spri... |
| February 12, 2009 | Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year| Click here to view a PDF version of this release
Strength and Diversity Drive Solid Financial Performance;
Productivity Transformation Delivering Savings;Industry-Leading Late-Stage Pipeline AdvancesKENILWORTH, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP - News) today reported financial results for the 2008 fourth quarter and full year."Schering-Plough delivered a very strong performance in 2008 - in the face of intensifying ... |
| February 03, 2009 | Brooke Shields and the Makers of COPPERTONE(R) Join Together to Launch COPPERTONE(R) NutraShield(TM) - New Sunscreen Contains Antioxidants That Promote Natural Skin Repair| Dual Defense(TM) Technology Latest Innovation from COPPERTONE(R) Solar
Research Center
KENILWORTH, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP), the makers of COPPERTONE(R), announced today that
actress and model Brooke Shields will become the spokesperson for the brand's
new beauty line, COPPERTONE(R) NutraShield(TM) with Dual Defense(TM) - a
broad spectrum sunscreen lotion enriched with antioxidants that promote
natural skin repair and combat ... |
| January 27, 2009 | Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients| KENILWORTH, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported that it has completed patient
enrollment in the boceprevir HCV SPRINT-2 study, a pivotal Phase III study in
treatment-naive patients. Together with the HCV RESPOND-2 study, a pivotal
Phase III study in patients who failed prior treatment that completed
enrollment in November 2008, the Company has fully enrolled its registration
studies for boceprevir, its lead investigational oral... |
| January 27, 2009 | New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available| - Introducing the First and Only Non-Drowsy Allergy Medicine in a
Liquid-Filled Capsule -
KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announces the introduction of new CLARITIN(R)
Liqui-Gels(R), the first and only non-drowsy allergy medicine in an
easy-to-swallow liquid-filled capsule. Now available over-the-counter,
CLARITIN(R) Liqui-Gels(R) provide powerful liquid relief for the worst allergy
symptoms without causing drowsine... |
| January 14, 2009 | U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder| Schering-Plough expects to respond to agency during first quarter
KENILWORTH, N.J., Jan. 14 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that the U.S. Food and Drug
Administration (FDA) has issued a complete response letter for SAPHRIS(TM)
(asenapine) sublingual tablets in the acute treatment of schizophrenia in
adults and in the acute treatment of manic or mixed episodes associated with
bipolar I disorder in adults as monotherapy. The action l... |
| January 14, 2009 | Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference| KENILWORTH, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) will provide a live audio webcast of a presentation by
Thomas P. Koestler, Ph.D., executive vice president and president,
Schering-Plough Research Institute, at the 27th Annual J.P. Morgan Healthcare
Conference in San Francisco on Monday, Jan. 12, at approximately 3:30 p.m.
(PST) (6:30 p.m. EST). Koestler is expected to talk about the company's R&D
pipeline and select projects in development.
... |
| January 09, 2009 | Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings| KENILWORTH, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) is scheduled to announce its sales and earnings
results for the 2008 fourth quarter and full year on Tuesday, Feb. 3, 2009.
At 8 a.m. (EST) on that day, Schering-Plough will conduct a conference
call to review results for the 2008 fourth quarter and full year. Fred
Hassan, Schering-Plough's chairman and CEO, and other members of management
will host the conference call.
To listen live t... |
| January 06, 2009 |
|
